Nasic (Xylometazoline Hydrochloride, Dexpanthenol)

Nasic works as a topical nasal decongestant that reduces swelling of the nasal mucosa and supports mucosal hydration.

• Common cold nasal congestion: relieves blockage and improves breathing.
• Sinusitis‑related nasal blockage: decreases swelling and eases sinus drainage.
• Allergic rhinitis: reduces obstruction and helps maintain nasal comfort.

• Xylometazoline Hydrochloride selectively stimulates alpha‑adrenergic receptors on nasal mucosal blood vessels, causing vasoconstriction and reduced edema. Dexpanthenol, a provitamin B5, promotes epithelial cell proliferation and restores mucosal hydration, supporting repair of the nasal lining after irritation.

Nasic may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nasal irritation or burning sensation
• Dryness of the nasal passages
• Sneezing or mild itching
• Headache
• Bitter taste after application
• Minor nosebleeds (epistaxis)

Serious or Rare Side Effects

• Severe hypertension or elevated blood pressure
• Cardiac arrhythmias
• Anaphylactic or severe allergic reactions
• Persistent nasal ulceration
• Rebound congestion (rhinitis medicamentosa) with prolonged use
• Vision changes or ocular pressure increase (rare).

Before using Nasic, consider the following safety measures.

• Use in children under 2 years: avoid unless directed by a healthcare professional.
• Pregnancy: safety not established; consult a physician before use.
• Concurrent nasal decongestants: increased risk of excessive vasoconstriction.
• Existing cardiovascular disease: use with caution and monitor blood pressure.
• Prolonged use beyond 3‑5 days: risk of rebound congestion; limit duration.
• Store at room temperature: keep in original container, protect from moisture and heat.

Nasic can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): may potentiate hypertensive effects.
• Systemic alpha‑adrenergic agonists (e.g., phenylephrine): additive vasoconstriction risk.
• Other nasal decongestants: risk of excessive local vasoconstriction and tissue damage.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: possible reduction in blood‑pressure‑lowering efficacy.
• Corticosteroid nasal sprays: monitor for increased local irritation.
• Antihistamines: may enhance sedation if combined with sedating antihistamines.